Andreas Goutopoulos Raised $75.5M for a Company That Was, on Paper, Just Him
He led chemistry at a big pharma for a decade, then walked out to build a radiopharma startup with no executive team and a single conviction: make the molecules stick.
The most unusual thing about Andreas Goutopoulos is not the science, though the science is genuinely unusual. It is that in the summer of 2025 he closed an oversubscribed $75.5 million Series A for a company that, on the org chart, was essentially one person. No CFO. No head of clinical. A founder, a thesis, and a stack of preclinical data.
Investors kept telling him this was not how it was supposed to work. Raising that kind of money at Series A without an executive team was, in his own words, his biggest challenge by far. It was very unusual at this stage, and it sometimes made it hard to be taken seriously. He said it plainly, the way a chemist reports a result that didn't come out clean the first time.
And yet the round oversubscribed. Four firms co-led it. To understand why, you have to go back past the fundraise, past Actithera, to a much older habit of mind: the belief that if you get the molecule right, a lot of other problems take care of themselves.
01 / THE THESISMake the medicine stick
Radioligand therapy is a deceptively simple idea. You take a radioactive isotope, attach it to a molecule that hunts for a specific protein on a tumor, and inject it. The molecule finds the cancer, the isotope delivers a dose of radiation up close, and healthy tissue is spared. The field is one of oncology's hottest corners.
The catch is timing. A lot of these molecules rinse off the tumor faster than the isotope can do its work, and some of the dose ends up parked in the kidneys, which limits how much you can safely give. Most of the field responded by chasing better isotopes. Goutopoulos, who had spent a career watching how small molecules bind and how long they last, asked a different question.
"We set out to bring structure-based and kinetics-driven thinking from small molecule drug design into the world of radiopharmaceuticals."Andreas Goutopoulos, Founder & CEO
The answer he landed on borrows a trick from pill chemistry: covalency. Instead of a molecule that docks onto the tumor and floats away, design one that forms a permanent chemical bond and holds on. Covalent binding is common in oral drugs. In radiation therapy, it was largely unexplored territory. When a 2024 Nature publication put the idea in print, it read like external validation of a bet he had already made.
The elegance is in the matching. If a molecule stays parked on a tumor for a long time, you can pair it with a longer-lived radionuclide whose energy is delivered over that same window. Match the half-life of the isotope to the residence time of the molecule, and you get fewer doses, a cleaner safety profile, and a wider therapeutic window. Actithera calls its platform isotope-agnostic - design the molecule first, choose the radionuclide to fit.
Covalent targeting
First-in-class covalent strategies tuned to hold onto tumors while clearing quickly from the rest of the body.
Residence & selectivity
Proprietary chemistry that extends how long a radioligand stays on target and sharpens its selectivity.
Isotope-agnostic
Molecules built to flex across radionuclides - alpha emitters, beta emitters, long half-life isotopes.
02 / THE ROAD INFrom anandamide to alpha emitters
The through-line of Goutopoulos's career is chemistry, applied to problem after problem. His doctorate at the University of Connecticut was in a very different world - cannabinoid receptor ligands and anandamide analogs, the molecules of the endocannabinoid system, work done in the orbit of the medicinal chemist Alexandros Makriyannis. It is a long way from cancer radiation, and also not far at all: both are exercises in designing a molecule to bind exactly what you want and nothing else.
From there he moved through the Center for Drug Discovery at Northeastern and then into industry, spending over a decade leading medicinal chemistry and discovery at EMD Serono, the biopharma arm of Merck KGaA. He came out of it with a track record most chemists would trade for - more than a dozen development candidates across multiple therapeutic areas, and a reputation for the unglamorous discipline of getting molecules to behave.
A career spent asking how a molecule binds, and how long it stays, turned out to be the exact preparation for a field obsessed with both.
Before Actithera, he served as an Entrepreneur-in-Residence at M Ventures, the venture arm connected to Merck, where he led the science for a set of oncology small-molecule biotechs. It is the kind of role that teaches a scientist to think like a builder: how a thesis becomes a company, what investors need to see, where good ideas die. In 2021, he stopped advising other people's companies and started his own.
03 / THE RAISETalk to everyone, then talk to them again
Here is the part founders will want to save. Goutopoulos did not raise $75.5 million because he had a polished team slide. He raised it as a company of one, which meant he had to sell the science and the person at the same time, over and over. His method was almost stubbornly simple.
"Talk to everyone, then talk to them again."On his fundraising method
He spoke with more than 250 venture funds. Not a blitz, a loop - each conversation a chance to sharpen the story and let the data catch up to the skepticism. His governing belief, the thing that kept him dialing, was that an investor's no is rarely final. A no was a not-yet, a question he hadn't answered well enough, a piece of validation he hadn't gathered.
So he gathered it. He built support among key opinion leaders who could vouch for the data, and he lined up soft commitments from senior talent who would join once the money landed - a way of showing investors the team that would exist without having to pretend it already did. It inverted the usual order. Most founders hire, then raise. He raised, then let the money summon the team.
When it closed, it oversubscribed. He called the syndicate - global, experienced, deep in the science - strong validation of the approach. Reading between the lines, the validation he cared about most was probably simpler than the money: after 250 conversations, enough serious people had looked at the chemistry and decided the guy might be right.
04 / THE ARCThe whole thing in one line
What makes the story worth telling is not the money. It is what the money was standing in for. Goutopoulos spent thirty years learning one thing extremely well - how a molecule binds, and how long it stays - and then found the field where that exact knowledge was the whole game. The depth did not make him cautious. It made him specific. He knew which unglamorous variable everyone else was treating as fixed, and he refused to treat it as fixed.
"We engineer our radioconjugates for extended retention within tumors... delivering more convenient dosing schedules and enhanced efficacy and safety for patients."Andreas Goutopoulos
The company now has to prove the thesis in the clinic, which is a longer and harder road than any raise. But the shape of the bet is clear, and it is his. Design the molecule to stay. Match the isotope to the wait. Talk to everyone, then talk to them again. For a company that started as one person and a conviction, that is a remarkably complete idea.